{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-091425","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.126958+00:00","generated_at":"2026-06-11T09:59:01.140415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Marker Therapeutics Q2 net income $2.5M; Cell Ready deal extends cash runway into Q4 2025","bullets":["Net income of $2.5M vs net loss of $9.2M in Q2 2022; cash and equivalents $18.1M.","Non-dilutive agreement with Cell Ready provides ~$19M cash and reduces annual operating expenses by ~$11M.","Appointed Juan Vera as CEO and Monic Stuart as CMO to lead restructuring and clinical advancement.","NIH awarded $2M SBIR grant for MT-401 AML program; EMA granted Orphan Drug Designation for MT-401.","First lymphoma patient dosed with MT-601 in Phase 1 APOLLO trial with no treatment-related adverse events."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-091425","json":"https://secwatch.observer/filing/0001104659-23-091425.json","markdown":"https://secwatch.observer/filing/0001104659-23-091425.md","text":"https://secwatch.observer/filing/0001104659-23-091425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/0001104659-23-091425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/tm2323634d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:59:01.140415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9efdc19e5176b0be3083708fb640504e3da7340d","claim":"Marker Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/0001104659-23-091425-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}